Form 4 for GILD Gilead Sciences
Accepted 2026-08-27 18:44:48 ET · period of report 2026-08-26 · accession 0001213307-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-27 18:44 | 2026-08-26 | GILD | WELTERS ANTHONY | Dir | M - OptEx | $61.06 | +18.0K | 23.2K | +348% | +$1.10M |
| DMT | 2026-08-27 18:44 | 2026-08-26 | GILD | WELTERS ANTHONY | Dir | S - Sale+OE | $148.62 | -18.0K | 12.9K | -58% | -$2.68M |
| DMT | 2026-08-27 18:44 | 2026-08-26 | GILD | WELTERS ANTHONY | Dir | M - OptEx | $0.00 | -18.0K | 5,569 | -76% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-26 | M | A | 7,718 | $60.67 | 20,612 | D | — | — | (F1) The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. |
| 2 | Common | Common Stock | 2026-08-26 | S | D | 3,118 | $148.31 | 17,494 | D | — | — | (F1) The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. (F2) Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
| 3 | Common | Common Stock | 2026-08-26 | S | D | 4,600 | $148.82 | 12,894 | D | — | — | (F1) The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. (F3) Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
| 4 | Common | Common Stock | 2026-08-26 | M | A | 10,282 | $61.35 | 23,176 | D | — | — | (F1) The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. |
| 5 | Common | Common Stock | 2026-08-26 | S | D | 3,402 | $148.24 | 19,774 | D | — | — | (F1) The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. (F4) Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
| 6 | Common | Common Stock | 2026-08-26 | S | D | 6,880 | $148.82 | 12,894 | D | — | — | (F1) The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. (F5) Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
| 7 | Derivative | Non-qualified Stock Option (Right to Buy) | 2026-08-26 | M | D | 7,718 | $0.00 | 0 | D | $60.67 · — to 2030-10-22 | 7,718 Common Stock | (F1) The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. (F6) 100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020. |
| 8 | Derivative | Non-qualified Stock Option (Right to Buy) | 2026-08-26 | M | D | 10,282 | $0.00 | 5,569 | D | $61.35 · — to 2032-05-05 | 10,282 Common Stock | (F1) The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. (F7) 25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021. |